Ryan Zeidan

Ryan Zeidan has a diverse work experience spanning over several companies and industries. Ryan is currently serving as the President and CEO of Sling Therapeutics since April 2021. Prior to this, they worked at Millendo Therapeutics from 2018 to 2021, initially as the Chief Development Officer and later as the Senior Vice President of Development.

Before joining Millendo Therapeutics, Ryan held various positions at Celgene, Novartis Oncology, Novartis Vaccines, and The Boston Consulting Group. At Celgene, they worked as the Executive Director, Global Program Leader from December 2016 to June 2018. Ryan was also an Executive Director of Planning and Operations at Novartis Oncology from September 2015 to December 2016.

During their tenure at Novartis Vaccines, Ryan served as the Head of Portfolio and Program Management from January 2015 to August 2015. Prior to that, they worked as a Senior Development Project Lead and a Project Lead from July 2014 to January 2015 and October 2012 to December 2014, respectively.

Ryan began their career at The Boston Consulting Group, where they worked as a Project Leader from January 2009 to October 2012. Ryan also gained experience as a Senior Scientist at Calando Pharmaceuticals from 2007 to 2008.

Ryan Zeidan has an extensive education history in the field of chemistry and chemical engineering. Ryan obtained their Bachelor of Applied Science (BASc) degree in Chemical Engineering and a Bachelor of Science (BS) degree in Chemistry from the Massachusetts Institute of Technology (MIT) between 1998 and 2002. Following this, they pursued a PhD degree in Chemistry and Chemical Engineering at Caltech from 2002 to 2007.